Cervical cancer development is driven by the transforming abilities of the human papillomavirus (HPV). Although the incidence of cervical cancer is fairly low in the United States due to the advent of the "pap" smear test and vaccination, 13,490 new cases and 4,200 deaths are projected in 2026 according to the NCI's Surveillance, Epidemiology, and End Results Program (SEER). The 5-Year relative survival rate is 68.8% (2016-2022). The Johns Hopkins University Cervical Specialized Program of Research Excellence (SPORE) was first funded in 2013, and its major activities are focused on the development of the next generation of novel preventive and therapeutic vaccines to improve treatment outcomes of patients with HPV-associated cervical cancer and its precursor lesions.
Johns Hopkins University Cervical Cancer SPORE
University of Miami, Emory University and Morehouse University PROMISE SPORE